NCT02260622 - Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

June 30, 2017

Study Completion Date

March 31, 2019

Conditions

Critical Limb Ischemia

Interventions

DRUG

rivaroxaban plus aspirin

Rivaroxaban 2.5 mg twice daily for 90 days (rivaroxaban will be started 6 to 8 hours after the finalization of the procedure) and 81 mg of ASA daily for 90 days

DRUG

clopidogrel plus aspirin

Clopidogrel 75 mg daily for 90 days (with a loading dose of 300 mg clopidogrel following PTA) and 81 mg of ASA daily for 90 days

Trial Locations (1)

K1Y4E9

The Ottawa Hospital, Ottawa